4-Demethylpenclomedine

Drug Profile

4-Demethylpenclomedine

Alternative Names: Clomet; DMPEN

Latest Information Update: 10 Feb 2010

Price : $50

At a glance

  • Originator Southern Research Institute
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 11 Jun 2008 Xanthus Pharmaceuticals has been acquired and merged into Antisoma
  • 16 May 2008 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 29 Mar 2007 Phase-I clinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top